Yes, i listened in on the earnings call yesterday morning. Not one analyst asked a question on trofinetide. They were all interested in Nuplazid and all the upcoming P3 trials occurring 2019 targeting different markets. It was a great presentation. The markets they are targeting in the P3 trials with Nuplazid are significantly larger than the current PDP market they are selling to now. If they have success then it will be a very significant re-rate. Big Pharmas would be looking very closely at Acadia.
Current Stock Valuation ., page-112
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |